Efficacy of Marine By-product Hydrolysate on the Reduction of Atopic Dermatitis Symptoms

Inclusion Criteria:

• Phototype: I to V;

• Subjects with atopic skin (with at least 1 visible xerosis + inflammation on thebody);

• Subjects with a history background of asthma, rhinitis and/or allergicconjunctivitis;

• Subjects with SCORAD between 8 and 30 (at least 50% or more having around 8-10);

• Subjects with BMI between 20 and 30 kg/m2 (limits included);

• Subjects who have not recently participated in another similar study;

• Willingness to take supplements for the duration of the study;

• Willingness not to use products likely to interfere with the test product (collagen,hyaluronic acid, anti-stress products);

• Willingness not to change lifestyle habits;

• Willingness to avoid intensive UV exposure;

• Use of contraception that should not be modified during the study.

• Healthy subject;

• Mentally healthy subject according to Investigator's opinion;

• Subject having given his/her free informed, written consent;

• Subject agrees to taking photograph and then use the image after itspseudonymization;

• Subject willing to adhere to the protocol and study procedures;

• Subject able to understand the study;

• Subject available to attend the study visits.

Exclusion Criteria:

• Pregnant or nursing woman or woman planning to get pregnant during the study;

• Cutaneous marks on the experimental areas, which could interfere with the assessmentof skin reactions;

• Subjects who have participated in the last 3 months or are currently participatingin another clinical trial that may interfere with the evaluation of the primaryendpoint (endpoint AD);

• Current administration of antibiotics;

• Known history of chronic disease such as congenital heart disease, liver or kidneydisease, or immune deficiency;

• Topical treatment with immunomodulators (tacrolimus or pimecrolimus) in the threemonths prior to registration;

• Application of moisturizing products on the experimental area the day of theinclusion of the study;

• Acute or chronic infectious diseases;

• Not meet inclusion criteria;

• Those undergoing aesthetic medicine (fillers, hyaluronic acid injections, botox)that could interference in the experimental area;

• Subjects suffering Alimentary/Eating disorders (i.e. bulimia, psychogenic eatingdisorders, etc.)

• Subjects having frequent stomach burn;

• Allergy or intolerance to any ingredient of the experimental food supplement;

• Subjects with diabetes mellitus;

• Fish and/or iodine allergy;

• Intestinal conditions or disorders (Crohn's disease, colitis, irritable bowelsyndrome, intestinal malabsorption...)

• Recent change, forecast of initiation of an hormonal treatment or change of theusual hormonal treatment during the study or 3 months before the starting of thestudy;

• Subject having undergone a surgery under general anesthesia within the previousmonth;

• Exposure in UVA ray sunbed during the 3 months before the start of the study on theexperimental area or during the study;

• Subjects protected by the law;

• Subject employed by EUROFINS PRODUCT TESTING, COSMETICS & PERSONAL CARE SPAIN,S.L.U.